培哚普利与钠催离联合治疗对预防中风后再中风的临床研究

THE COMBINATION OF PERINDOPRIL AND INDAPAMIDE SR ON THE PROTECTION AGAINST RECURRENT STROKE

为了评价培哚普利与钠催离联合治疗对预防中风再发的作用 ,选择了 80名有中风或一过性脑缺血发作史患者 ,随机分为两组 ,分别用培哚普利 (4mg/d)与钠催离 (2 .5mg/d)联合治疗或相应安慰剂治疗 4年 ,观察治疗前后血压、血钾、血肌酐、MMSE计分及中风、心血管事件和残疾的发生情况。研究结果发现 :两组药物联合治疗降压作用显著且平稳 ,血肌酐有下降趋势 ,血钾无显著变化 ,MMSE计分增加 ;与安慰剂对照组相比 ,治疗组发生中风 (10 %比 30 % ) ,总心血管事件 (10 %比 30 % ) ,认知功能障碍 (5 %比 2 2 .5 % )和残废 (2 .5 %比 2 5 % )的危险性降低 ,P均 <0 .0 5。本文结果提示 :培哚普利与钠催离联合治疗能降低再中风危险 ,减少心血管事件发生 ,改善认知功能和生活质量 ,且副作用少 ,耐受性好。

Objective:To access the protective effects of perindopril and indapamide SR on recurrent stroke. Methods:80 patients with a history of stroke or transient ischemic attack were randomly assigned to treatment with perindopril(4mg/d) and indapamide SR(2.5mg/d) or matching placebo for 4 years. Blood pressure, serum creatinine,MMSE count,stroke, cardiovascular events and disability were measured. Results:Active combination therapy reduced blood pressure significantly and steadily. The level of serum creatinine tended to decrease and MMSE count increased. Compared with placebo,active treatment significantly reduced total stroke ( 10%比30%) , total cardiovascular events ( 10%比30%) , cognitive decline (5%比22.5%) ,disability (2.5%比 25%) ,all P <0.05. Conclusion:Our findings show that the combination of perindopril and indapamie reduced the risk of recurrent stroke and cardiovascular events,improved cognitive function and life quality, minimised adverse effects and was well tolerated.